

## Patient 1

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	20						Lenalidomide
29	19	<6,60	1446.00	<0,01	3.80		
48	18						
57							Lenalidomide discontinued
62	19	<6,85	1200.00	<0,01	4.74		
99	22	<6,00	932.00	<0,01	4.47		
153	22	<6,00	1136.00	<0,01			
164	Negative						
176						30% of bonemarrow leukocytes	
178							Bortezomib, dexamethasone
201	13	<6,00	15.90	<0,38			
229	9						
245	9	<6,00	6.65	NQ			
256	9						
264	Negative						
293	Negative						
331							Treatment stopped --> CR
335	Negative						
424	Negative	7.95	11.40	0.70			
487	Negative	6.28	16.10	0.39			
579	11						
656	13						
697	18	<6,30	955.00	<0,01			
718	19	<6,30	1062.00	<0,01	2.74		
784	26	<6.30	2200	<0.01			

### Clinical information Patient 1-9.

Clinical data obtained from routine tests during the course of disease. Indicated is the sampling day relative to the first sample available for this study, serum protein electrophoresis result (SPEP), free light chain data for kappa and lambda light chains by nephelometry as well as the ratio between them, urine protein electrophoresis (UPEP) results, the outcome of bone marrow evaluation by flow cytometry and a summary of the main treatment events.

Patient 1 (continued)

816					monoclonal plasma cell population present	Bortezomib, cyclophosphamide, dexamethasone (VCD)
883	8	<6.60	<4.90	NQ		
904	8	<6,60	<4,90	NQ		
909	8	<6,60	<4,90	NQ		
969						Treatment stopped --> sCR
973					no monoclonal plasma cell population	
1000	Negative	<6.60	<4.50	NQ		
1021	Negative					
1072	Negative					
1131	Negative	9.16	26.40	0.35		
1170	Negative					
1320	8					
1359	8					
1387	9	4.69	746.00	<0,01		
1422	10	<4.00	464.00	NQ		
1456						Lenalidomide, cyclophosphamide, prednisone

Patient 2

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	18	6.71	5.83	1.15		monoclonal plasma cell population present	VCD
33							Treatment stopped --> VGPR
41	5	<6,00	7.83	NQ		no monoclonal plasma cell population	
94							HDM + ASCT
153	5						
155							Lenalidomide maintenance
260	5	21.80	26.60	0.82			
315	Negative	25.50	27.50	0.93			
329						no monoclonal plasma cell population	
400	Negative	15.70	22.00	0.71		no monoclonal plasma cell population	
482	Negative	12.80	19.10	0.67			
511	5	16.20	18.50	0.88	Negative		
518	5						
539	6	22.80	15.70	1.45			
563	11	46.70	12.80	3.65			
584	19	275.0	10.40	26			
591						0.02% monoclonal plasmacells	
610							Lenalidomide, cyclophosphamide, prednisone

Patient 3

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	17						
21	20						
63	10						
88	5						
119							Carfilzomib, lenalidomide, dexamethasone
120	5						
144	5	<6,60	<4,70	NQ			
176	5						
203	5						
233	5	<6,00	7.05	NQ			
259	Negative	<6,00	8.30	NQ			
289	Negative						
315	Negative						
329	Negative						
343	Negative						
357	Negative						
392	Negative						
406	Negative						
435	5						
459	5						
514	5						
549	5						
571	5						
602	5						
632	5						
660	5						
687	5						
714	10	14.10	5.75	2.45			
730	9	15.00	<5,20	NQ			
738	10	18.50	<4,90	NQ			
749	6					3% monoclonal plasmacells	
760	15	33.50	5.46	6.14			
819							Lenalidomide, prednisone, cyclophosphamide
1031							Treatment stopped

Patient 4

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	5	6.40	30.20	0.21			Carfilzomib, thalidomide, dexamethasone (Carthadex)
13	5	8.65	27.00	0.32	Negative		
41	5	6.64	12.40	0.54			
65	5	5.69	10.30	0.55			
90							Treatment stopped --> VGPR
114	5	<5,40	5.97	NQ	Negative		
149							HDM + ASCT
204	5	16.40	12.20	1.34	Negative		
241							Carthadex consolidation
252	Negative				Negative		
262	Negative	<5,40	<5,20	NQ			
279	Negative						
303	Negative						
321	Negative						
333							Consolidation stopped
391	Negative	8.89	14.40	0.62	Negative		
468	Negative	9.31	17.50	0.53	Negative		
521	Negative	<6.60	15.40	NQ			
577	Negative				Negative		
625	Negative	6.95	11.40	0.61	Negative		
688	Negative	7.69	10.40	0.74	Negative		
745	Negative	5.86	18.00	0.33	Negative		
827	Negative	8.77	14.80	0.59	Negative		
892	Negative	9.22	19.10	0.48	Negative		
958	Negative	5.77	11.80	0.49	Negative		
1016	Negative	7.75	19.10	0.41	Negative		
1093	Negative	6.08	16.60	0.37	Negative		
1165	Negative	8.76	19.80	0.44	Negative		
1219	Negative	10.60	19.60	0.54	Negative		
1289	Negative	11.70	19.90	0.59	Negative		
1373	5	13.40	22.80	0.59	Negative		
1437	5	20.20	24.70	0.82	Negative		
1465	5	21.40	25.70	0.83	Negative		
1512	5	21.10	25.30	0.83	Negative		

## Patient 5

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	5	5.46	5.79	0.94			Carthadex
15	5	5.78	8.78	0.66			
38							Treatment stopped --> VGPR
46	5	<6,60	6.10	NQ	Negative		
60	5	6.98	7.05	0.99			
76	5	10.30	9.41	1.10			
99							HDM + ASCT, after Carthadex consolidation
155	5						
186	Negative	<6,00	4.55	NQ			
196	Negative						
211	Negative	<6,00	4.96	NQ	Negative		
238	Negative	<6,00	4.59	NQ			
277	Negative						
340	Negative						
400	5				Negative		
470	5	8.19	9.12	0.90	Negative		
497	Negative	12.00	11.40	1.05			
543	Negative	12.60	24.80	0.51	Negative		
588	Negative	10.10	15.30	0.66	Negative		
635	Negative						
673	Negative						
732	Negative						
792	Negative				Negative		
866	Negative				Negative		
925	Negative				Negative		
981	Negative				Negative		
1036	Negative				Negative		
1100	Negative						
1159	Negative				Negative		
1225	Negative				Negative		
1288	Negative				Negative		
1446	5				Negative		
1519	5						
1546	5				Negative		
1581	5				Negative		
1651	5						
1679	5				Negative		
1707	5						

## Patient 6

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	26						
37	11						
65	7						
97	5	394.00	4.60	85.65			
118							Lenalidomide and dexamethasone
135	6						
166	5						
173	5						
180	5						
191	5	47.80	4.64	10.30			
219	5						
233	5	33.10	4.15	7.98			
250	5	22.40	<3,90	NQ			
275	5	18.10	7.67	2.36			
288	5	15.80	<5,20	NQ			
306	5	12.50	<5,20	NQ			
334	5	10.40	<5,20	NQ			
358	5	7.39	<5,20	NQ			
387	5	8.50	<5,20	NQ			
420	Negative						
422							Treatment stopped
450	Negative						
474	Negative	10.50	<5,20	NQ		0.06% monoclonal plasmacells (CD38+/CD19-/CD45-/CylgKappa+/CD56+), 0.02% normal plasmacells.	
488	Negative	11.50	<5,20	NQ			
548	5	22.50	<5,20	NQ			
611	5	33.30	6.29	5.29			
671	5	170.00	5.55	30.63			
702	5						

## Patient 7

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	29						Bortezomib and dexamethasone
15	14						
19	13						
48	5						
72	5						
91	5						
105	Negative	13.00	<4,70	NQ			
112	Negative					no monoclonal plasma cell population	
215							Treatment stopped --> sCR
296	Negative						
344	Negative					no monoclonal plasma cell population	
426	Negative						
511	Negative						
853	25						
884							Bortezomib, lenalidomide, prednisone
890	29						
895	28						
897	24						
918	17						



Patient 8

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	5						Dasatinib, dexamethasone, lenalidomide
27	5						
56	5						
99	5						
154	5						
210	5						
238	5						
281	5						
309	5						
337	5						
364	5						
396	5						
420	5						
434	Negative						
448	Negative						
463	Negative						
481	Negative						
491	Negative						
523	5						
533	5						
557	Negative						
558							Treatment stopped --> VGPR
567	Negative						
596	5						
641	5						
673	5						
736	5						
909	5						
1035	5						
1155	5						
1434	5						
1547	5						
1799	5						

Patient 9

Day	SPEP (M-protein g/L)	Free light chain kappa (mg/L)	Free light chain lambda (mg/L)	K/L ratio	UPEP g/24h	Bone marrow	Treatments
0	15						
87	17						
108	18						
231	24						
298	22						
389	25						
406	28					9.2% of bone marrow leukocytes	
437	29						
451	27						
462	11						
496							Panabinostat, bortezomib, dexamethasone
508	5						
546	5						
558	5						
567	5						
595	5						
618							Treatment stopped --> VGPR
620	5						
733	5						
847	Negative						
966	Negative						
990						0.9% of bonemarrow leukocytes	
1159	Negative						
1263	Negative						
1382	Negative						
1505	5						
1631	5						
1705	5						
1769	5						
1823	5						
1914	5						